Ranibizumab in treating age-related macular degeneration
Conclusions1. Monthly treatment with ranibizumab has a substantial inhibitory effect on the course of disease compared to photodynamic therapy or sham injection in patients with neovascular age-related macular degeneration - in followup ≤2 years.2. Monthly treatment improves vision to a substantiall...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Stockholm
Swedish Council on Health Technology Assessment (SBU)
May 21, 2008, 2008
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Conclusions1. Monthly treatment with ranibizumab has a substantial inhibitory effect on the course of disease compared to photodynamic therapy or sham injection in patients with neovascular age-related macular degeneration - in followup ≤2 years.2. Monthly treatment improves vision to a substantially higher degree in patients treated with ranibizumab compared to those who received photodynamic therapy or sham injection - in followup ≤2 years.3. Scientific evidence is insufficient regarding the effects of treatment when delivered less frequently than once per month, or for periods exceeding 2 years.4. It is unclear whether treatment can be discontinued, or if further treatments are necessary to maintain the effects.5. Scientific evidence is insufficient to assess the cost-effectiveness of the method |
|---|---|
| Physical Description: | 1 PDF file (3 pages) |